Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Ondine Biomedical, Inc. (LSE:OBI): Could Commercial Adoption Of Infection-Prevention Products Reshape the AIM market Investment Case?

The most relevant recent area of investor attention is commercial adoption of infection-prevention products; this does not establish an independently verified price catalyst on 29 October.

Ankur Sharma | 29 October 2026

Kooth PLC (LSE:KOO): Could Contract Delivery And Public-Sector Commissioning Reshape the AIM market Investment Case?

The most relevant recent area of investor attention is contract delivery and public-sector commissioning; this does not establish an independently verified price catalyst on 29 October.

Ankur Sharma | 29 October 2026

Why EDX Medical Group plc Is on the Watchlist Today and What Could Matter Next (LSE:EDX)

EDX Medical is focused on diagnostic technologies, where validation, laboratory adoption, partnerships and recurring test volumes are key to commercial progress. Investors will be watching evidence of customer uptake, regulatory compliance, cash consumption, intellectual-property development and the timeline from technical capability to repeatable revenue. …

Ankur Sharma | 29 October 2026

Why Fusion Antibodies plc Is on the Watchlist Today and What Could Matter Next (LSE:FAB)

Fusion Antibodies provides antibody engineering and discovery services. Recent October updates included a contract win and a research and trading update. Investors will be watching the size and timing of contract revenue, repeat business, laboratory utilisation, cash runway, customer concentration and whether its technology …

Ankur Sharma | 29 October 2026

Why ImmuPharma plc Is on the Watchlist Today and What Could Matter Next (LSE:IMM)

ImmuPharma remains a development-stage biotechnology story, with recent updates covering its P140 programme, patent work and development support for Kapiglucagon. Investors will be watching clinical and regulatory milestones, partner engagement, cash resources and the pace at which research programmes can reach value-defining evidence. This …

Ankur Sharma | 29 October 2026

Oxford Nanopore: Can Real-Time Sequencing Reach Profitable Scale?

Oxford Nanopore Technologies plc shares fell 0.77% today, according to the market data provided, dropping 1.8p to233.2p.

Divya Sood | 29 October 2026

OXB: The Cell and Gene Therapy Specialist Navigating a Demanding Biotech Market

OXB Company plc shares fell 1.87% today, according to the market data provided, dropping 10p to525p.

Divya Sood | 29 October 2026

Why is HUTCHMED (LSE:HCM) in focus after the US FDA granted sovleplenib orphan drug designation?

In an announcement released at 07:00 on 29 October 2026, HUTCHMED said the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia (ITP). The company said the designation "underscores the potential of sovleplenib …

Ankur Sharma | 29 October 2026

Why is Haleon (LSE:HLN) in focus after its Q3 trading statement and £500m buyback launch?

Haleon released two regulatory announcements on the London Stock Exchange this morning. At 07:00 it issued its "2026 Q3 Trading Statement" covering the third quarter of the year ending 31 December 2026. At 07:05 it followed with a separate announcement confirming the commencement of …

Ankur Sharma | 29 October 2026

Cardiogeni (LSE:CGNI) pushes audited accounts to mid-November as shares stay suspended

Cardiogeni, a UK clinical-stage biotechnology company traded on the AQSE Growth Market under the ticker CGNI, issued an update on the timing of its audited annual accounts for the financial year ended 31 March 2026.

Ankur Sharma | 29 October 2026
Support

Hi! How can we help you today?

Loading…